Sentence examples for between treatment groups while from inspiring English sources

Two-sample t-tests were used to test for differences between treatment groups, while paired tests were used to examine changes over time within treatment groups.

Protein abundance of glucokinase, GK, did not change significantly between treatment groups, while that of fatty acid synthase, FAS, significantly decreased in fish injected with either dose of LNA-122i, compared to saline-injected control fish.

Thus in some cases, manipulation of sucrose content also allowed carbohydrate, protein, or fat content to differ between treatment groups, while in others diets were matched in regard to macronutrient composition (fat:protein carbohydrate) but differed in regard to SFA, PUFA, or fibre content.

Data were normally distributed and were analyzed using one-way Analysis of Variance (1-way ANOVA, p < 0.05); pairwise t-test was used to test the differences of means between treatment groups, while Dunnett's one-tailed t-test was used to evaluate differences between "reference" embryos and "resistant" embryos, respectively.

The expression of ATP-binding cassette sub-family G member 8, abcg8 (df = 2; F = 1.175; p > 0.05; Figure  7G), did not change between treatment groups, while significant increases in the expression of ATP-binding cassette sub-family G member 5, abcg5 (df = 2; F = 4.035; p < 0.05; Figure  7G) were found in trout injected with 25 μg/ g LNA-122i.

Haemoglobin changes from baseline to day 28 were comparable between treatment groups (data not shown) while the change from baseline to the last available data was significantly higher in the DHA-PQP group than in the AL group (ITT: 17.0±18.18 g/L vs 14.27±18.54 g/L, p = 0.007; ePP: 17.19±17.96 g/L vs 15.07±18.56 g/L, p = 0.044).

While differences between treatment groups were not observed for peak vertical force (Max Fz, Max Fzz did follow a similar profile toward reduced values in rats with NP alone, (non-significance, ANOVA P-value = 0.411).

While significant differences between treatment groups and placebo were observed in laboratory analytes and vital signs, those differences were generally small and not considered to be clinically relevant.

The change in prothrombin time and the hepatic SOFA, while being statistically different between treatment groups, exhibited a negative correlation with the DrotAA treatment effect (namely, its direction was opposite that anticipated for a beneficial treatment effect).

While frequencies per category were similar between treatment groups at baseline, more duloxetine than placebo patients fell into the 2 best categories after 12 weeks.

While there was no relevant difference is OS between treatment groups, it is worth considering the possible role that second-line therapy could have had on survival.